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ABSTRACT  
Background: Chikungunya fever is a globally spreading mosquito-borne disease that shows an 
unexpected neurovirulence. Even though the neurological complications have been a major cause of 
ICU-admission and death, up to date, there is no systematic analysis of their spectrum available. 
Objective: To review evidence of neurological manifestations in Chikungunya fever and map their 
epidemiology, clinical spectrum, pathomechanisms, diagnostics, therapies and outcomes. Methods: 
Case report and systematic review of the literature following established guidelines. All cases found 
were assessed using a 5-step clinical diagnostic algorithm assigning categories A to C, category A 
representing the highest level of quality. Only A- and B-cases were considered for further analysis. 
After general analysis, cases were clustered according to geospatial criteria for subgroup analysis. 
Results: 36 of 1,196 studies were included, yielding 130 cases. Nine were ranked as category A 
(diagnosis of Neuro-Chikungunya probable), 55 as B (plausible), and 51 as C (disputable). In 15 cases, 
alternative diagnoses were more likely. Patient age distribution was bimodal with a mean of 49 years 
and a second peak in infants. 50% of the cases occurred in patients < 45 years with no reported 
comorbidity. Frequent diagnoses were encephalitis, optic neuropathy, neuroretinitis and Guillain-
Barré-Syndrome. Neurologic conditions showing characteristics of a direct viral pathomechanism 
showed a peak in infants and a second one in elder patients, and complications and neurologic 
sequelae were more frequent in these groups. Autoimmune-mediated conditions appeared mainly in 
patients over 20 years and tended to show longer latencies and better outcomes. Geospatial 
subgrouping of case reports from either India or Réunion revealed diverging phenotypic trends 
(Réunion: 88% direct viral vs. India 81% autoimmune). Conclusions: Direct viral forms of Neuro-
Chikungunya seem to occur particularly in infants and elderly patients, while autoimmune forms have 
to be also considered in middle-aged, previously healthy patients, especially after an asymptomatic 
interval. This knowledge will help to identify future Neuro-Chikungunya cases and to improve 
outcome especially in autoimmune-mediated conditions. The genetics of Chikungunya virus might 
play a key role in determining the course of neuropathogenesis. With further research, this could prove 
diagnostically significant. 
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ABBREVIATIONS 
Ae = Aedes (a genus of mosquitoes) 
ADEM = Acute disseminated encephalomyelopathy 
BBE = Bickerstaff’s brainstem encephalitis 
CHIKF = Chikungunya fever 
CHIKV = Chikungunya virus  
d = days 
DOI = Day of illness 
DWI = Diffusion-weighted imaging  
ECSA = East, Central, and South African 
ENMG = electroneuromyograph 
GBS = Guillain-Barré-Syndrome 
IFN = Interferon 
MFS = Miller-Fisher-Syndrome 
mRS = modified Rankin scale 
PRISMA = Preferred reporting items for systematic reviews  
  and meta-analyses 
rtPCR = Reverse transcription Polymerase chain reaction 
y = years 
 
Introduction    
 
Chikungunya fever (CHIKF) is a mosquito-borne disease caused by the Chikungunya virus 
(CHIKV), a RNA virus first described in 1952 in today’s Tanzania [1]. Until recently, CHIKF 
was regarded as a non-fatal disease restricted to Africa and Asia, marked by fever, 
polyarthralgia and rash [2-4]. However, the last decade brought forth a “new face” of CHIKF 
due to: 1) The “Asian tiger mosquito“ Aedes (Ae.) albopictus spreading to the Indian Ocean, 
South America, Europe and the USA [5]. 2) The spread of a new CHIKV strain, probably 
from Kenya in the early 2000s, to the Indian ocean [6]. There it met up with Ae. Albopictus 
and underwent an adapting mutation that boosted the transmission by the new vector [7,8], 
causing major epidemics with thousands of cases [9]. 3) Increased air travel exports CHIKV 
to other countries and may provoke autochthonous transmission by local Aedes populations 
[10,11]. This has happened to a limited extent in Italy, France and the USA, whilst CHIKV 
has spread to 45 countries in Central/South America since 2013, resulting in another 1.7 
million suspected cases [12-15]. The resulting upsurge of cases is likely the reason for an 
accumulation of life-threatening complications, suggesting CHIKF as a potentially fatal 
disease that may cause broad systemic involvement (Fig. 1). 
Thereby, neurological complications take center stage: Accounting for up to 25% of 
atypical cases and up to 60% of severe atypical cases, they are a major cause of ICU 
admission and death in CHIKF [16,17]. Reports range from encephalitis, optic neuritis, 
myeloradiculitis to Guillain-Barré-Syndrome (GBS), causing drastic sequelae such as mental 
disability, blindness and persisting paralysis – also in young and previously healthy persons 
[18-26]. In many cases, neurological signs start after a symptom-free interval of 1-3 weeks, 
pointing to an autoimmune process [21-26]. Given the challenge of this variety and the 
forecast that CHIKF will continue its spread to more temperate regions such as the USA and 
Europe in the future [27], neurologists should be aware of the typical aspects of Neuro-
Chikungunya. 
However, to our knowledge, no systematic analysis of neurological complications in 
CHIKF has been published to date. Nor is there a critical appraisal of the evidence in 
individual case reports. Therefore, we performed a systematic review of all published cases, 
combined with a case report assessment. The aim was to assess the possible clinical spectrum 
of neurological involvement regarding patient age and origin, comorbidity and time from 
disease onset, and to review the diagnostics, therapies, pathomechanisms, encountered 
complications and outcomes of Neuro-Chikungunya.  
 
 
Fig. 1  Possible disease courses of CHIKF 
 
According to Economopoulou et al.[16], severe atypical CHIKF is defined as the  
patient needing support of at least 1 vital function (such as mechanical ventilation).  
Further sources: manifestation rate [3,4,9], chronic arthralgia [28-32], atypical and  
severe cases and death [16,17,33-37]. 
 
 
 
  
Case report 
 
A 74-year-old man with hypertension, dyslipidaemia and suspended nicotine abuse, 
experienced fever, arthralgia and rash while on holiday in Tahiti. Symptoms disappeared 
within 48h. On 7th day of illness (DOI) he noticed hypoesthesia of the hands and gait 
difficulties. The following morning, he couldn’t walk and suffered from hoarseness, dyspnoea 
and, finally, loss of consciousness. Paramedics discovered ventricular tachycardia, which was 
reversed by defibrillation. After hospital transfer, he was intubated and ventilated due to 
respiratory insufficiency. Cranio-thoracic CT yielded no findings. Laboratory findings were 
unspecific. ECG abnormalities called for a coronary angiography and stenting of the left 
anterior descending artery. MRI scan showed diffusion-weighted imaging (DWI) restrictions 
in the pons, the EEG revealed an “alpha coma”. After sedation was discontinued, the patient 
remained unresponsive and brainstem reflexes were absent. Severe hypoxic encephalopathy 
due to cardiac arrest was suspected and palliative strategy recommended. However, 
perceiving him as being responsive, the patient’s wife insisted on full life-sustaining measures 
and repatriation.  
Upon admission to the Neurocritical Care Unit, University Hospital Zurich, on 21st 
DOI, the patient presented with multiple cranial nerve palsies (complete ophthalmoplegia, 
facial diplegia, absence of corneal/gag reflex, swallowing and tongue movements), flaccid 
tetraplegia and areflexia. However, basic communication was possible through head 
movements. MRI reevaluation suggested rhombencephalitis. CSF examination revealed 
cytoalbuminologic dissociation and intrathecal synthesis of IgM/IgA with oligoclonal bands 
in CSF and serum. CSF glucose and lactate levels were normal. CSF-microbiology was 
negative, as was PCR for herpes simplex 1/2- and varicella zoster virus. Serum tested 
negative for T. pallidum, B. burgdorferi, HIV, hepatitis B/C-, tick-borne encephalitis- and 
human herpes virus 1-5. Serum tested positive for Anti-CHIKV-IgM and IgG and for anti-
dengue IgG. Search for paraneoplastic, antiganglioside and anti-MAG antibodies was 
negative. EEG showed minor generalized alterations without epileptiform potentials. An 
electroneuromyography (ENMG) objectified severe distally accentuated axonal 
polyneuropathy. Taken together, the diagnosis of a Bickerstaff’s brainstem encephalitis 
(BBE)-Miller-Fisher-syndrome (MFS)-GBS-overlap was retained. After a 1-week plateau, the 
patient deteriorated, prompting therapy with i.v. immunoglobulins on 33rd DOI. The patient 
regained control over swallowing and eye movements but non-verbal communication did not 
return to previous levels. Follow-up MRI revealed progressive rhombencephalitis (Fig. 2A-
C). Negative CHIKV rtPCR from serum and CSF reinforced the assumption of an 
autoimmune pathomechanism, prompting therapy with Methylprednisolone i.v. on 51st DOI, 
leading to a gradual improvement of alertness and patient transfer to a neuro-rehabilitation 
center. After 4 months motor function of proximal limbs improved to muscle grade 2/5. One 
year after onset ventilation could be switched to non-invasive ventilator support. Latest follow 
up - 1.5 years after onset - showed normal mental status and cranial nerve function, but 
persisting, distally accentuated hypaesthesia and paresis of limbs with near complete palsy of 
hands and feet. For detailed case information see appendix 1. 
 
 
  
Systematic review 
 
Methods 
A systematic review was performed, following the “preferred reporting items for systematic 
reviews and meta-analyses“ (PRISMA) guidelines [38]. Appendix 2 contains the review 
protocol. Publications had to meet all following criteria: (1) patients with confirmed CHIKV 
infection showing neurological symptoms; (2) CHIKV infection confirmed by presence of 
viral RNA, specific IgM or fourfold increase in IgG titres in serum or CSF [9]; (3) peer-
reviewed case report/series, observational study or scientific letter; (4) data provided for each 
patient, enabling verification of diagnosis; (5) case occurred after 2000. Cases were excluded 
if any of the following applied: (1) confirmed concurrent infection such as malaria, dengue or 
Zika fever; (2) vaccination one month prior to symptom onset; (3) isolated paresthesias of 
hands (CHIKV-mediated carpal tunnel syndrome); (4) children with simple febrile seizure 
only. 
We searched MEDLINE (through PUBMED and OVID), EMBASE, WEB OF SCIENCE 
and SCOPUS from January 1, 2000 to December 1, 2015, combining “Chikungunya“ and a 
broad list of neurological conditions, using both index terms and free text, proximity 
operators and truncation symbols. No further limits were applied. For complete search 
strategy see appendix 2. Applying the predefined eligibility criteria, the records were screened 
by TC as shown in Fig. 3.  
Data extraction into a pilot tested data file was performed twice (by TC), with an interval 
of two months. For coding rules see appendix 2. Authors were contacted if case similarity 
suggested double counting, or if data was missing or ambiguously stated (both coded as 
missing). The quality of the included cases was assessed by a clinical diagnostic decision tree 
(Fig. 4), using extracted data items and two new criteria assessed for each case report: A) are 
clinical signs consistent with the diagnosis? B) are other etiologies sufficiently excluded? To 
answer these questions consistently, a list of relevant neurological diagnoses was defined 
using the National library of Medicine’s Medical Subject Headings-Thesaurus, UpToDate and 
relevant literature (appendix 2). The answers were added to the general data extraction sheet. 
This enabled to program the entire decision tree as an algorithm, which assigned the cases to 
the quality categories A, B and C (Fig. 4). After assignment, each case was reviewed 
manually for algorithm adherence. Statistical analysis was performed using IBM©-SPSS©-
software (version 22).  
  
Results  
 
1. Description of studies and case report assessment 
A total of 1,196 records were screened (Fig. 3). 36 articles were included in the systematic 
review, comprising 131 patients (nine redundant cases were excluded). All authors were 
contacted for missing data. 21 replied, supplying data for 51 cases; prompting the exclusion of 
two further cases. After adding abovementioned case report, the total case number was 130.  
All were assessed for quality using the algorithm in Fig. 4. In 15 cases, clinical signs 
were inconsistent with the obtained diagnosis or alternative diagnoses were more likely. Of 
the remaining 115 cases, nine qualified as category A (probable Neuro-Chikungunya case), 55 
as B (plausible) and 51 as C (disputable). Due to weak evidence level of category C, only A- 
and B-cases were used for further analysis (Tab. 1). The A-cases are described in appendix 3.                 
 
 
 
 
 
 
Fig. 3  PRISMA scheme showing the study selection process with reasons for exclusion 
 
Fig. 4 Algorithm used for case report assessment with number of cases for each decision 
 
Abbreviations: Dx=diagnosis; DD=differential diagnosis; rtPCR=reverse transcription PCR. 
*Additional studies are: imaging (MRI, CT, transfontanellar ultrasound), nerve conduction studies (ENMG, 
VEPs), EEG, lumbar puncture; in case of neuroretinitis/papillitis: ophthalmoscopy showing fundus alterations. 
 
Tab. 1 List of reported diagnoses for the 64 cases of category A and B 
 
Abbreviations: ADEM=acute disseminated encephalomyelopathy; MFS=Miller-Fisher-Syndrome;  
GBS=Guillain-Barré-Syndrome.
2. Patient Characteristics 
Patient age distribution of the 64 A- and B-cases approached a bell-shaped curve spanning 
from 20-80 years (y), with a second peak in infants/children. In adults, mean age was 49y 
(median 48, SD=17). The sex ratio was 41% females to 59% males. Patient comorbidity was 
25%, most frequently due to cardiovascular problems (32%) and diabetes (25%). 50% (32/64) 
of cases occurred in younger patients (<45y) with no reported comorbidity. 
 
3. Clinical presentation of Neuro-Chikungunya  
Neurological symptoms were preceded by classical CHIKF symptoms: fever in 98%, 
arthralgia in 71% and rash in 45%; complete triad was present in 36%. Neurological 
symptoms started on average 10 days (d) after initial symptom onset (median 7, range 1-53). 
However, the corresponding histogram revealed a two peaks trend in latency; encephalitis 
accounting for the first peak (mean 3.5d), neuro-ophthalmological diagnoses accountingfor 
the second (mean 23.2d). Time between initial symptoms and GBS onset varied from very 
short (2d), through short (7d, 8d) to long (14d, 19d). 19% (12/64) of the patients were 
asymptomatic between initial symptoms and neurological complaints.   
Frequent diagnoses were encephalitis, optic neuropathy, neuroretinitis, GBS (Tab. 1). 
Encephalitis (N=27) was marked by altered mental status (100%) and fever (96%), 
accompanied by seizures (52%) and focal neurological deficits (56%), e.g. paresis of limbs, 
asymmetrical hypertonia, pyramidal signs or myoclonus. Two cases showed marked 
brainstem involvement (appendix 4). Optic neuropathy (N=18) presented with defective 
vision and relative afferent pupillary defect. 16 cases were subdiagnosed as papillitis – three 
showing involvement of other cranial nerves – and two as retrobulbar neuritis – one showing 
bilateral external ophthalmoplegia, facial palsy, hemiparesis and unconsciousness (appendix 
5). GBS (N=5) presented with distally accentuated quadriparesis and hypo-/areflexia, more 
pronounced in lower limbs, accompanied by facial palsy in all five cases (3/5 bilateral).  
 
4. Diagnostics  
Serum tested positive for CHIKV infection in all 64 cases, CSF tested positive in 31/33 cases. 
In encephalitis, serum rtPCR was positive in 65% (13/20) and IgM in 77% (17/22), while in 
CSF, rtPCR was positive in 62% (13/21) and IgM in 80% (12/15). In GBS, rtPCR was 
typically negative and IgM positive (serum and CSF). In ADEM, optic neuropathy and 
neuroretinitis, serum IgM was positive and rtPCR negative, where tested. CSF basic 
biochemistry was pathological in 77% (N=35); in encephalitis it frequently showed 
transudative (39%, 9/23) or exsudative CSF syndrome (26%, 6/23). The typical CSF 
syndrome in GBS was cytoalbuminological dissociation (80%, 4/5; for definitions see 
appendix 3). MRI was performed in 42/64 cases; in encephalitis it was pathologic in 83% 
(10/12). ENMG was performed in all GBS (MFS) cases and showed a demyelinating (2/6) or 
combined axonal/demyelinating pattern (4/6).  
 
5. Suspected pathomechanism, therapy, complications and outcome 
Depending on the treating physicians’ assumption of the underlying pathomechanism (direct 
viral versus autoimmune), therapies were either purely symptomatic (40%) or also 
immunosuppressive (60%). Fig. 5 summarizes the epidemiological and clinical aspects of the 
two groups. While assumingly direct viral forms showed a peak in infants (and a second one 
in elder patients), autoimmune forms occurred almost exclusively in patients over 20y, with a 
peak in the middle-aged. Encephalitis therapy was mainly symptomatic (23/27), whereas all 
cases of optic neuropathy, neuroretinitis and ADEM were treated with steroids with good 
(66%) or partial response (33%). GBS spectrum cases were treated with steroids, ivIG or 
both, with varying responses.  
58% (37/64) of cases developed complications, mainly altered level of consciousness 
(49%), seizure (18%), need for intubation (18%). In 20% they were severe, e.g. respiratory 
failure (n=10), cardiovascular instability (n=5), sepsis (n=3) or intracranial hypertension 
(n=2).  Cumulation of complications was observed in the very young and the elderly and in 
CNS affections. Outcome at last follow-up was full recovery in 29%, partial recovery in 50%, 
no recovery in 10% and death in 11%; or, in terms of the modified Rankin scale (mRS): no 
significant disability (mRS 0-1) in 43%, slight to moderate disability (mRS 2-3) in 29% and 
moderately severe to severe disability (mRS 4-5) in 15%. Death occurred in seven cases due 
to neurological damage (N=4) or other organ decompensation (N=2, cause unclear in 1 case). 
A cumulation of severe outcomes was observed in children and elderly (mRS≥4 in 83% of 
patients <12y and in 58% of patients >65y vs. 0-11% in other age groups) and in CNS 
affections (mRS≥4 in 46% vs. 4% in peripheral forms). Cases with suspected autoimmune 
pathomechanism showed better outcome than cases with suspected direct viral 
pathomechanism (Fig. 5). 
 
Fig. 5 Suspected pathomechanisms according to the physicians’ treatment   
  
Abbreviations: mRS=modified Rankin scale; SD=Standard deviation; GBS=Guillain-Barré-Syndrome;  
ADEM=Acute disseminated encephalomyelitis; BBE=Bickerstaff’s encephalitis; MFS=Miller-Fisher-Syndrome. 
ª Treatment known in 60 cases.  ° Data available for 15 viral cases and 21 autoimmune cases. 
Moderate complications: altered level of consciousness, seizure, need for intubation. 
Severe complications: respiratory failure, cardiovascular instability, sepsis, intracranial hypertension.  
6. Phenotypic trends in outbreak-specific subgroups 
We categorized the case reports into six outbreak subgroups: Réunion (2005-2006), India 
(2006-present), Italy (2007), Thailand (2009), the Caribbean (2013-2014) and Pacific Islands 
(2011-2015). Showing the largest number of case reports (Fig. 6) and a more or less even 
representation of all age groups, Réunion and India were chosen for further analysis. 
Comparison of CHIKV action in these subgroups revealed a stark distinction: while 88% of 
the Réunion cases suffered from an assumingly direct viral pathomechanism, the majority 
from India (82%) suffered from possibly autoimmune-mediated conditions. This correlated 
with the neurological site affected (Reunion 78% CNS affection vs. India 69% PNS 
affection). Concerning patient outcome, no disability (mRS=0) was the most frequent 
outcome in Réunion (42%) and India (50%); however, second commonest outcome in India 
was slight disability (mRS=2, 25%) versus death in Réunion (mRS=6, 21%).    
Fig. 6 Phenotypes and genotypes in different outbreak regions 
       
Discussion  
This review confirms Neuro-Chikungunya as a severe form of CHIKF. Age distribution was 
bimodal with a mean at 49y and a second peak in infants. 50% of cases occurred in younger 
patients (<45y) with no reported comorbidity. Neurological symptoms were usually preceded 
by fever and arthralgia, with two latency peaks. Frequent diagnoses were encephalitis, optic 
neuropathy, neuroretinitis and GBS, less frequent ADEM and combined 
encephalomyeloradiculopathies. Autoimmune-connoted diagnoses were seen mainly in 
patients over 20y and tended to show longer latencies and better outcomes. Complications and 
adverse outcomes were more frequent in children and elderly and in CNS affections. 
The strength of this study is its systematic analysis of Neuro-Chikungunya cases 
published between 2000-2015, including an in-depth assessment of each reported diagnosis. 
Thus, 51% (66/130) of cases were excluded due to weak evidence for a causality between 
CHIKV infection and neurological symptoms (=category C, see appendix 6 for frequent 
pitfalls). Nevertheless, this retrospective review has its limitations, as the case mix is probably 
distorted by publication bias, thus requiring comparison with larger-scale observational field 
studies.  
While hospital-based studies of neurological complications during epidemics 
(Réunion 2005/06, India 2006) suggest a preponderance of (mostly encephalitic) CNS 
affections in elderly with comorbidities (44-57%) [17,39,40], we found a bimodal age 
distribution with a peak in the middle-aged and a second one in the very young. There are two 
explanations: first, our study may show an overrepresentation of autoimmune-connoted 
diagnoses such as GBS and optic neuropathies; these patients tended to be younger and 
healthier. Likewise, a recent series on CHIKV-associated GBS found a mean of 48y and 33% 
comorbidity [41]. Secondly, our study contains some pediatric cases, which account for the 
peak in the very young. Indeed, a large study on CHIKV encephalitis during the Réunion 
outbreak found the highest incidence rates among the youngest and oldest (38% <1y and 38% 
>65y) [18]. Neonates constitute a major risk group for Neuro-Chikungunya: in perinatally 
infected women vertical transmission rates of up to 50% were observed, leading to 
neurological symptoms and neurodevelopmental delay in up to 50% of infected neonates [42-
44]. In short, the epidemiology of Neuro-Chikungunya might be summarized by three 
overlapping paradigms: 
1) Peak of CNS affections in neonates and infants 
2) Peak of autoimmune, often PNS affections in middle-aged 
3) Peak of CNS affections in elderly with comorbidities 
Regarding clinical aspects of Neuro-Chikungunya, field studies report similar findings: 
fever (91-100%) and arthralgia (83-100%) are frequent precursors, while rash is rarer (25-
44%) [18,39,40]; encephalitis generally starts in this acute phase of CHIKF, while GBS tends 
to occur subacutely, after a symptom-free interval [18,39-41]. Either way, fever and 
arthralgia followed by neurological symptoms may indicate Neuro-Chikungunya in 
(travellers from) endemic areas. Concerning detection of CHIKV in Neuro-Chikungunya, our 
findings are in line with the “rule of thumb“ for general CHIKF: serum rtPCR sensitive up to 
7 DOI, IgM ELISA starting from 3-4 DOI [3]. Reported CSF changes in 61-85% (77% in our 
review) suggest that CSF biochemistry is useful, although CSF changes seem to be less 
frequent in children [18]. The need for early (<7d) DWI-weighted MRI is stressed, as other 
modalities lack sufficient sensitivity [18,39,40]. Nerve conduction studies are decisive in 
recognizing peripheral nerve affection, especially if cranial neuropathies mimic central 
damage [45]. The average rate of severe complications in Neuro-Chikungunya is confirmed to 
be ~20%; the need for intensive care support in encephalitis is reportedly higher (42%, N=24) 
[18]. This corresponds to our finding: complications were more frequent in the youngest and 
elderly, the main encephalitis targets. Figures on outcome in Neuro-Chikungunya report no 
sequelae in ~45%, persisting disability in ~35% and death in ~20% [17,18,39]. In our review, 
we saw more disability (44% mRS 2-5) and less mortality (11%), possibly due to the 
overrepresentation of autoimmune mediated conditions.  
For clinical practice it is key to consider the pathomechanism involved in Neuro-
Chikungunya cases. Basic research points towards at least two paradigms: a direct viral and 
an autoimmune one. A) A direct viral CNS infection is increasingly demonstrated. In mice 
with deficient interferon (IFN) signalling, CHIKV crosses the choroid plexus and infects the 
meninges and ependyma, thereby possibly affecting underlying neuronal cells or even the 
stem cell niche [46-48]. In vitro, CHIKV infects mouse brain neurons, astrocytes and 
oligodendrocytes, causing apoptosis in the first two [49]. Additionally, astrocytes produce 
IFN and proapoptotic factors, possibly causing further bystander damage and disrupting the 
blood-brain-barrier [49,50]. These findings are assigned to human neonates and elderly 
people due to their weaker innate and adaptive immune response [46,48]. This is supported by 
a high rate (92%) of CHIKV rtPCR positivity in infected neonates’ CSF and short latency 
between initial CHIKF signs and encephalitic symptoms [39,40,44]. The direct viral 
mechanism suggests the clinical use of neutralizing antibodies in neonates born to CHIK-
viremic mothers and development of vaccines and antiviral drugs on astrocyte level [50].  
B) An autoimmune response triggered by CHIKV seems probable, as numerous cases 
show longer latency between initial signs and neurological symptoms and respond to 
immunosuppressants. Furthermore, the autoimmune nature of some diseases observed in 
CHIKF is increasingly recognized: GBS, MFS and BBE have been proposed recently to form 
one broad spectrum with a common autoimmune pathomechanism: after infection with 
certain pathogens, autoantibodies are formed due to molecular mimicry between the pathogen 
and nerve tracts [51]. These antibodies are either directed against the myelin sheath of 
Schwann-cells (antigen unknown), causing demyelination and slowing of nerve conduction, 
or against gangliosides located in the node of Ranvier, causing intermittent conduction blocks 
and, with time, persistent axonal damage [52]. This can be linked to CHIKV by two 
arguments: 1) there has been a rise in GBS incidence during CHIKV epidemics in La Réunion 
and French Polynesia [41,53]; 2) anti-ganglioside antibodies were found in CHIKV-
associated GBS cases [41]. However, Neuro-Chikungunya cases with documented anti-
ganglioside antibody screening remain scarce, while the screening itself is subject to some 
uncertainties [52]. Besides, proving molecular mimicry would require deciphering the 
CHIKV structure mimicking neural structures [54]. Nevertheless, we suggest considering 
CHIKV as a possible trigger for autoimmune mediated neurological conditions, especially for 
all GBS-MFS-subtypes as classified by Wakerley et al [51]. Thus, even less familiar forms 
might be recognized and treated in time.  
Proposing two paradigms of Neuro-Chikungunya pathogenesis (direct viral CNS infection 
with short latency versus autoimmune PNS affection with longer latency), two caveats are 
necessary: First, short latency can be autoimmune: although autoimmune-connoted cases 
tended to have longer latencies, one GBS case showed a latency of only two days [26]. This 
might be due to reactivation, as recurring GBS tends towards shorter latency [55]. Therefore, 
short latency does not rule out an autoimmune-mediated disease. Second, central can be 
autoimmune: although autoimmune-connoted cases tended to show peripheral nerve affection, 
there were three cases of suspected autoimmune brainstem encephalitis responding to 
immunosuppressants (case report, appendix 4) and three ADEM cases, an illness generally 
considered autoimmune-mediated [56]. Thus, central affections in CHIKF should also be 
matched against possible autoimmune-mediated conditions. 
By analyzing the geographic and temporal origins of the case reports we wanted to 
determine whether the genetic and antigenic landscapes of CHIKV play a role in its 
neuropathogenesis. Phylogenetic analysis of CHIKV indicates three distinct genotype groups: 
West African, ECSA (East, Central and South African) and Asian [2,57]. Indeed, sequence 
analysis of the envelope glycoprotein 1 (E1) region of the CHIKV genome revealed a 
sequence similarity of only 78% between isolates of the West African and the ECSA and 
Asian genotypes [2]. CHIKV not only exhibits genetic heterogeneity; studies reported that 
isolates also have distinct antigenic phenotypes [2,57].  
 Interestingly, further analysis of Réunion and India cases revealed diverging clinical 
and pathogenetic phenotypes. Most patients from Réunion showed signs of a likely direct 
neurotoxic pathomechanism, while patients from India those of an autoimmune one. This is 
mirrored by predominantly CNS affection in Réunion cases compared to mainly PNS 
affection in India cases. Hypothetically, this might be due to adaptive mutations being 
accumulated by the virus during outbreak, pushing it (incidentally) in a direct neurotoxic or 
neuro-autoimmune direction. Indeed, an analysis of the microevolution of CHIKV during the 
Réunion outbreak showed that the virus – though most closely related to the ECSA genotype 
– underwent nucleotide and amino acid changes, resulting in an epidemic strain genetically 
different from the initial strain; most prominently, a mutation (A226V) in the E1 glycoprotein 
occurred, probably as a result of CHIKV adaptation to its new vector, Ae. Albopictus  
[7,20,58]. This microevolution could account for the abundance of atypical and 
neuropathogenic cases emerging during the outbreak.  
Another study used in vivo infection of mice with the ECSA vs. Asian strain 
comparing their neurovirulence. While the strains were similarly neuroinfectious, the Asian 
group showed higher mortality rates and higher apoptosis gene expression, while the ECSA 
group showed upregulation of genes involved in CNS protection [59]. 
Overall, the genetics of CHIKV could be of clinical relevance once the genetic 
elements that contribute to neurovirulence are understood. The abovementioned comparisons 
suggest the possibility to characterize CHIKV neuropathogenesis based on strain specificity, 
which could help to choose among treatment options in cases of Neuro-Chikungunya.  
To this end, mapping mutations during outbreaks and their effect on CHIKF manifestation as 
well as improving our knowledge on CHIKV genetics in general is imperative. 
 
 
 
 
  
Conclusions 
Neuro-Chikungunya is a severe form of CHIKF with a broad spectrum. Fever and arthralgia, 
followed by neurological symptoms may indicate Neuro-Chikungunya in travellers from 
endemic areas. Direct viral CNS infections with short latencies are seen in infants and in 
elderly with comorbidities, while autoimmune-mediated conditions have also to be considered 
in middle-aged, previously healthy patients, especially after an asymptomatic interval. Careful 
attention is required to discern direct viral from autoimmune conditions: while short latency 
and CNS affection suggest a direct viral pathomechanism, autoimmune conditions have been 
observed in these situations, too. Adverse outcomes occur especially in infants and elderly 
with direct viral CNS affection. By contrast, outcome seems better in cases with suspected 
autoimmune pathomechanism and use of immunosuppressants. Geospatial and temporal 
clustering of case reports revealed diverging phenotypic patterns, suggesting that strain-
specific genetics may play a diagnostically relevant role in disease pathomechanism and 
course. To confirm these emerging trends and provide better evidence for causality between 
CHIKV infection and neurotoxicity/-autoimmunity, it is time to move from case reports/series 
and epidemiological correlations to case-control studies and RCTs. 
  
FIGURES & TABLES 
Fig. 1   Possible disease courses of CHIKF 
Fig. 2 MRI on 38th DOI showing progress of rhombencephalitis from pons up to the left  
  thalamus and internal capsule 
Fig. 3   PRISMA scheme showing the study selection process with reasons for exclusion 
Fig. 4 Algorithm used for case report assessment with number of cases for each decision 
Tab. 1 List of reported diagnoses for the 64 cases of category A and B 
Fig. 5  Suspected pathomechanisms according to the physicians treatment   
Fig. 6 Phenotypes and genotypes in different outbreak regions 
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